Flightpath Biosciences: Commitment and Direction in Lyme Disease Treatment
May 5, 2026 A Message to the Lyme Disease Community To the Lyme Disease Community, Guided by Patients: Our Core Principle At Flightpath Biosciences, our decisions are guided by the patients living with Lyme Disease. We are committed to clear, honest communication about our promise to deliver safe, effective treatment solutions. Strategic Update: Shifting Focus […]
Flightpath Biosciences Accelerates Clinical Pipeline with New Drug License and Unveils New Corporate Identity to Support Next Phase of Growth
Detroit, MI – November 13, 2025 — Flightpath Biosciences, a clinical-stage biotechnology company focused on treating infection-associated complex diseases, today announced a major advancement with the licensing of its newest drug candidate, FP530 (Forazemin), a peptide deformylase inhibitor rediscovered by co-founder Kim Lewis, PhD, a Flightpath scientific cofounder and Head of Northeastern University’s Antimicrobial Drug […]
Flightpath Biosciences Begins Human Clinical Testing of the World’s First Narrow-Spectrum Antibiotic Targeting Lyme Disease
DETROIT, Michigan, May 10th, 2024 — Flightpath Biosciences Inc., a clinical-stage life sciences company developing therapeutics to treat infectious diseases, announced today that the first healthy volunteer participants have been dosed in its Phase I clinical trial of FP-100 (hygromycin A), an orally-available, narrow-spectrum antimicrobial drug candidate. The single center, prospective, randomized, double-blind, placebo-controlled study […]
Flightpath Biosciences and the Forsyth Institute Enter into a Co-Development Agreement Targeting Treatments for Oral Diseases
Detroit, MI and Boston, MA, October 3, 2023 Flightpath Biosciences, Inc announced today that it has signed a landmark development agreement with the Forsyth Institute, a globally recognized leader in the fields of oral health research and clinical care. The development agreement contemplates a multi-indication and multi-year deal to develop new products and intellectual property […]
Flightpath Licenses the First Antibiotic that Selectively Kills Lyme Disease Spirochetes
– Research demonstrates the ability of FP-100 to enter spirochetal bacteria but not gut symbionts giving it a significant advantage versus standard broad-spectrum antibiotics used to treat Lyme disease, Adult and Congenital Syphilis, Periodontal Disease and Tropical Treponematoses – Narrow-spectrum antimicrobial therapeutics kill the bacteria causing the disease but don’t destroy the gut microbiome OR […]
